TrialJournal of immunotherapy (Hagerstown, Md. : 1997)2013
Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.
Ben C Creelan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
24 papers cite it
this paperpooled ittrialcites it